Evidence map›Paper›PMID 34358101›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

An Adenovirus Vector Expressing FMDV RNA Polymerase Combined with a Chimeric VLP Harboring a Neutralizing Epitope as a Prime Boost Strategy to Induce FMDV-Specific Humoral and Cellular Responses.

Giselle Rangel, Verónica Martín, Juan Bárcena, Esther Blanco, Alí Alejo

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Foot-and-mouth disease in Asia.Virus research · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Giselle RangelCentro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain.ORCID 0000-0001-6825-3803
Verónica MartínCentro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain.ORCID 0000-0003-1486-1656
Juan BárcenaCentro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain.ORCID 0000-0001-6050-0654
Esther BlancoCentro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain.ORCID 0000-0001-8413-4222
Alí AlejoCentro de Investigación en Sanidad Animal (INIA, CSIC), Ctra de Algete a El Casar de Talamanca, Valdeolmos, 28130 Madrid, Spain.ORCID 0000-0002-1613-6063
Centro de Investigación en Sanidad AnimalInstituto de Investigaciones Científicas y Servicios de Alta Tecnología · PA

Funding

Ministerio de Ciencia e Innovación AGL2016-76445-R
6 · The paper itself

Abstract

Foot and mouth disease is a highly contagious disease affecting cattle, sheep, and swine among other cloven-hoofed animals that imposes serious economic burden by its direct effects on farm productivity as well as on commerce of farmed produce. Vaccination using inactivated viral strains of the different serotypes is an effective protective measure, but has several drawbacks including a lack of cross protection and the perils associated with the large-scale growth of infectious virus. We have previously developed chimeric virus-like particles (VLPs) bearing an FMDV epitope which induced strong specific humoral responses in vaccinated pigs but conferred only partial protection against homologous challenge. While this and other FMD vaccines under development mostly rely on the induction of neutralizing responses, it is thought that induction of specific T-cell responses might improve both cross protective efficacy as well as duration of immunity. Therefore, we here describe the development of a recombinant adenovirus expressing the highly conserved nonstructural FMDV 3D protein as well as its capacity to induce specific T-cell responses in a murine model. We further describe the generation of an FMDV serotype C-specific chimeric VLP and analyze the immunogenicity of two different prime-boost strategies combining both elements in mice. This combination can effectively induce both humoral and cellular FMDV-specific responses eliciting high titers of ELISA and neutralizing antibodies anti-FMDV as well as a high frequency of IFNγ-secreting cells. These results provide the basis for further testing of this anti FMD vaccination strategy in cattle or pig, two of the most relevant natural host of this pathogen.

Indexed as

adenovirus vaccinefoot and mouth disease virusprime-boost vaccinationvirus-like particle

Identifiers

PMID34358101
PMCPMC8308840
OpenAlexW3179909268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.